Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
Covington
UBS
Deloitte
Cantor Fitzgerald
Boehringer Ingelheim
Dow
AstraZeneca

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,427,578

« Back to Dashboard

Which drugs does patent 9,427,578 protect, and when does it expire?


Patent 9,427,578 protects ZECUITY and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 9,427,578

Title:Pharmacokinetics of iontophoretic sumatriptan administration
Abstract: Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
Inventor(s): Sebree; Terri B. (Gladwyne, PA), Pierce; Mark (Essex, CT), O'neill; Carol (Phoenixville, PA)
Assignee: Teva Pharmaceuticals International GmbH (Rapperswil-Jona, CH)
Application Number:14/185,485
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Branded Pharm
ZECUITY
sumatriptan succinate
SYSTEM;IONTOPHORESIS202278-001Jan 17, 2013DISCNYesNo► Subscribe► SubscribeY METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,427,578

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,155,737Pharmacokinetics of iontophoretic sumatriptan administration► Subscribe
8,597,272Pharmacokinetics of iontophoretic sumatriptan administration► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,427,578

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2008358027► Subscribe
Australia2015238858► Subscribe
Canada2727927► Subscribe
Eurasian Patent Organization025505► Subscribe
Eurasian Patent Organization201100056► Subscribe
European Patent Office2303392► Subscribe
Spain2603274► Subscribe
Israel209756► Subscribe
Israel238603► Subscribe
Japan2011524784► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Mallinckrodt
Boehringer Ingelheim
Dow
Baxter
Merck
Chinese Patent Office
Colorcon
Fuji
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot